2X1:ETR
Abivax SA
84,05 €
arrow_downward
-0,12%(-0,100) 1 d
2 oct, 10:15:55 GMT+2 · EUR
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de 2X1...
Abrir
83,15 €
Alto
84,05 €
Bajo
83,15 €
Cap. burs.
7343,80 M
Vol. medio
1,78 mil
Volumen
14,00
Máximo en 52 sem.
137,40 €
Mínimo en 52 sem.
60,85 €
BPA
-5,20 €
N.º de empleados
98
Abrir
83,15 €
Alto
84,05 €
Bajo
83,15 €
Cap. burs.
7343,80 M
Vol. medio
1,78 mil
Volumen
14,00
Máximo en 52 sem.
137,40 €
Mínimo en 52 sem.
60,85 €
BPA
-5,20 €
N.º de empleados
98
Noticias
De fuentes web y partners de noticias
MarketBeat
·
hace 15 horas
Abivax (NASDAQ:ABVX) Stock Price Down 5.1% - Should You Sell?
TipRanks
·
hace 1 día
Abivax to Showcase Extensive Obefazimod Data at UEG Week 2026
Perfil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Acerca de Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Empleados98
Fundación4 dic 2013
Sede-
Sector-
Sitio webabivax.com